Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia
Oncology Nurse Advisor ,
August 01, 2017 Patients with chronic myelomonocytic leukemia may experience a good response with decitabine.
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
Overview of attention for article published in Leukemia, June 2017
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (88th percentile)
-
High Attention Score compared to outputs of the same age and source (80th percentile)
Readers on
- mendeley
- 56 Mendeley